Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus TAZICEF.
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
750 mg to 1.5 g intravenously every 8 hours; for severe infections, up to 1.5 g every 6 hours.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.6 hours (prolonged to 15-22 hours in severe renal impairment, CrCl <10 mL/min); requires dose adjustment in renal failure
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic